Clinical Trial Update: A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing certoparin to unfractionated heparin for prevention of thromboembolic events in acutely ill medical patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Certoparin (certoparin)
• Unfractionated Heparin (unfractionated heparin)

Snippet

Sponsor: Novartis | Conditions: Thromboembolism | Phase 3 | Status: COMPLETED